JP2011523359A - 抗ＰｉｒＢ抗体 - Google Patents

抗ＰｉｒＢ抗体 Download PDF

Info

Publication number
JP2011523359A
JP2011523359A JP2011509642A JP2011509642A JP2011523359A JP 2011523359 A JP2011523359 A JP 2011523359A JP 2011509642 A JP2011509642 A JP 2011509642A JP 2011509642 A JP2011509642 A JP 2011509642A JP 2011523359 A JP2011523359 A JP 2011523359A
Authority
JP
Japan
Prior art keywords
antibody
pirb
lilrb
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523359A5 (pt
Inventor
ジャスヴィンダー アタワル，
マーク テシエ−ラヴィーン，
ヤン ウー，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011523359A publication Critical patent/JP2011523359A/ja
Publication of JP2011523359A5 publication Critical patent/JP2011523359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011509642A 2008-05-13 2009-05-13 抗ＰｉｒＢ抗体 Pending JP2011523359A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US61/052,949 2008-05-13
US12/208,883 2008-09-11
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 2008-12-09
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration
PCT/US2009/043757 WO2009140361A1 (en) 2008-05-13 2009-05-13 ANTI-PirB ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2011523359A true JP2011523359A (ja) 2011-08-11
JP2011523359A5 JP2011523359A5 (pt) 2012-07-05

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509642A Pending JP2011523359A (ja) 2008-05-13 2009-05-13 抗ＰｉｒＢ抗体

Country Status (15)

Country Link
EP (1) EP2291405A1 (pt)
JP (1) JP2011523359A (pt)
KR (1) KR20110011676A (pt)
CN (1) CN102089327A (pt)
AR (1) AR071777A1 (pt)
AU (1) AU2009246443A1 (pt)
BR (1) BRPI0912769A2 (pt)
CA (1) CA2723430A1 (pt)
IL (1) IL209129A0 (pt)
MX (1) MX2010012299A (pt)
PE (1) PE20091969A1 (pt)
RU (1) RU2010150754A (pt)
TW (1) TW200950808A (pt)
WO (1) WO2009140361A1 (pt)
ZA (1) ZA201007976B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
JP6162219B2 (ja) * 2012-04-17 2017-07-12 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
EP3728318A2 (en) 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
MX2021000009A (es) 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
WO2021222544A1 (en) 2020-05-01 2021-11-04 Ngm Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092165A2 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453540A4 (en) * 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092165A2 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
WO2009140361A1 (en) 2009-11-19
ZA201007976B (en) 2012-02-29
EP2291405A1 (en) 2011-03-09
RU2010150754A (ru) 2012-06-20
KR20110011676A (ko) 2011-02-08
BRPI0912769A2 (pt) 2015-10-13
CA2723430A1 (en) 2009-11-19
CN102089327A (zh) 2011-06-08
MX2010012299A (es) 2010-12-06
PE20091969A1 (es) 2010-01-15
AR071777A1 (es) 2010-07-14
IL209129A0 (en) 2011-01-31
TW200950808A (en) 2009-12-16
AU2009246443A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
US20230295297A1 (en) Anti-trem2 antibodies and methods of use thereof
US20220251219A1 (en) Methods of use of anti-sortilin antibodies for treating a disease, disorder, or injury
CN107106679B (zh) 抗trem2抗体及其使用方法
CN108137702B (zh) 抗siglec-7抗体及其使用方法
US7943329B2 (en) Modulators of neuronal regeneration
JP2011523359A (ja) 抗ＰｉｒＢ抗体
US20090232794A1 (en) Modulators of neuronal regeneration
US20090285803A1 (en) ANTI-PirB ANTIBODIES
WO2020023920A1 (en) Anti-siglec-5 antibodies and methods of use thereof
US20100047232A1 (en) Modulators of neuronal regeneration
ZA200210086B (en) Agonist Anti-TRK-C monoclonal antibodies.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140408